U.S. markets open in 8 hours 4 minutes
  • S&P Futures

    3,889.50
    -9.25 (-0.24%)
     
  • Dow Futures

    31,452.00
    -57.00 (-0.18%)
     
  • Nasdaq Futures

    13,258.25
    -21.50 (-0.16%)
     
  • Russell 2000 Futures

    2,262.30
    -12.50 (-0.55%)
     
  • Crude Oil

    60.02
    -0.62 (-1.02%)
     
  • Gold

    1,715.80
    -7.20 (-0.42%)
     
  • Silver

    26.21
    -0.47 (-1.75%)
     
  • EUR/USD

    1.2031
    -0.0029 (-0.24%)
     
  • 10-Yr Bond

    1.4460
    0.0000 (0.00%)
     
  • Vix

    23.35
    -4.60 (-16.46%)
     
  • GBP/USD

    1.3888
    -0.0033 (-0.23%)
     
  • USD/JPY

    106.8430
    +0.1130 (+0.11%)
     
  • BTC-USD

    48,491.68
    +2,141.74 (+4.62%)
     
  • CMC Crypto 200

    974.36
    -12.29 (-1.25%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Sage Therapeutics to Present at BMO 2020 Growth & ESG Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the BMO 2020 Growth & ESG Conference on Wednesday, December 9, 2020 at 3:00 p.m. ET.

A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201203005946/en/

Contacts

Investor Contact
Jeff Boyle
617-949-4256
Jeff.Boyle@sagerx.com

Media Contact
Maureen L. Suda
617-949-4289
maureen.suda@sagerx.com